The Bionanotechnology Frontier
Imagine every cancer patient's genome being sequenced to design proteins that bind to the mutations of that patient in order to destroy their tumor. This idea is not impossible. And soon these paradigms will become the societal norm.
Bionanotech is the emerging field of research that allows us to personalize and in real-time diagnose and treat disease with a variety of evolving technologies. The implications are not only in healthcare, but also in agriculture, software, manufacturing, the environment, and new sectors that don't even exist yet. Bionanotech is a new frontier that we must understand and apply to our own work in order to accelerate the technologies.
Riley Ennis is a biotechnology and healthcare entrepreneur who is focused on revamping the broken infrastructure of the industry through personalized devices and therapies. He is founder of a biotechnology startup, Immudicon, and was recently selected as a Thiel Fellow in 2013. The company was founded based on three years of research on a cancer vaccine technology that teaches the immune cells of the body to recognize and remove tumors. The vaccine has been recognized by CNN, Google X, ABC, the American Society of Microbiology, Fox News, the GE Focus Forward Competition, the Intel International Science Fair, and the National Young Inventors Gallery. Before starting the Thiel Fellowship in 2013, Riley was a rising Junior at Dartmouth College, pursuing a double major in economics and biology, and he worked at the Dartmouth Hitchcock-Medical Center on cancer nanotechnology research projects as a Dartmouth Science Scholar.